Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $108.95M fell 18.5% year over year, behind the -17.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Selling, general & admin amounted to 21.8% of revenue in FY2025, down 7.5 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 16 analysts of $666.19M (+39.1%) for the fiscal year ending Dec 2026, a step up from the -14.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$108.95M-15.1% QoQ
Last fiscal yearDec 2025
$478.94M-14.1% YoY
LTMMar 2026
$467.04M-17.3% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.5%-5.1%+13.3 pp
1 year-14.1%+39.1%+53.2 pp
3-year CAGR+2.0%+0.3%-1.7 pp
5-year CAGR-3.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
478.94M USD
Year-over-year change
-14.1%
4-year CAGR
+14.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 selling, general & admin of $467.04M is the 3rd highest of the 11 companies compared; the peer median is $85.16M.
  • Its year-over-year change of -17.3% is the lowest of 11, against a peer median of +20.4%.
  • Selling, general & admin amounts to 21.4% of revenue for SRPT, versus a peer median of 61.0%.
SRPT Competitors Peer median
Selling, General & Admin for SRPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.32B +22.1%+16.3%27.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M +66.3%+37.9%61.0%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$467.04M -17.3%+2.0%21.4%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$351.33M +8.3%+2.1%34.8%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$157.94M +14.5%+9.9%239.0%
DYNDyne Therapeutics, Inc.LTM Jun 2026$91.25M +50.5%+35.3%—
WVEWave Life Sciences Ltd.LTM Mar 2026$79.08M +23.9%+14.3%110.1%
SLDBSolid Biosciences Inc.LTM Mar 2026$40.91M +18.8%+10.3%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M +58.7%+29.7%—
PEPGPepGen Inc.LTM Mar 2026$22.56M +1.9%+16.6%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$20.62M +11.6%+2.3%—
Peer median (excluding SRPT) $85.16M+20.4%+15.3%61.0%

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.